Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Abiraterone + Prednisone
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Abiraterone Zytiga CB7630 Hormone - Anti-androgens 57 Zytiga (abiraterone) inhibits cytochrome P-450c17, resulting in decreased androgen synthesis (PMID: 25560485). Zytiga (abiraterone) is FDA approved for patients with metastatic castration-resistant prostate cancer (FDA.gov).
Prednisone Adasone Dehydrocortisone Adasone (prednisone) is a corticosteroid which functions as an immunosuppressant and anti-inflammatory agent and which may stimulate apoptosis in tumor cells (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06378866 Phase II Degarelix Goserelin Darolutamide Relugolix Triptorelin Enzalutamide Histrelin acetate Abiraterone + Prednisone Leuprolide Apalutamide Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial (DIVINE) Recruiting USA 0
NCT04446117 Phase III Enzalutamide Atezolizumab + Cabozantinib Abiraterone + Prednisone Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02) Active, not recruiting USA | POL | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG 10
NCT03706365 Phase II Abemaciclib + Abiraterone + Prednisone Abiraterone + Prednisone A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Active, not recruiting USA | ROU | NLD | FRA | ESP | DNK | DEU | AUS 3
NCT02429193 Phase II Enzalutamide Abiraterone + Prednisone Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA (BARRIER-P) Completed CAN 0
NCT06136650 Phase III Abiraterone + Prednisone Dexamethasone + Fludrocortisone + ODM-208 Enzalutamide A Study of MK-5684 Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) Recruiting USA | TUR | SWE | SVK | ROU | NZL | LVA | LTU | ITA | ISR | IRL | HUN | GRC | GBR | FRA | EST | ESP | DEU | CZE | CAN | BRA | AUS 17
NCT03419234 Phase II Abiraterone + Prednisone Abiraterone + Cabazitaxel + Prednisone Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Hormone-Sensitive Prostate Cancer Previously Treated With Docetaxel Active, not recruiting USA 1
NCT04876651 Phase III Docetaxel Enzalutamide 177Lu-J591 + Abiraterone + Prednisolone Abiraterone + Prednisone 177Lu-J591 + Abiraterone + Prednisone 177Lu-J591 + Enzalutamide Abiraterone + Prednisolone 177Lu-J591 + Docetaxel The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only Recruiting NZL | AUS 0
NCT06496581 Phase III Enzalutamide Abiraterone + Docetaxel + Prednisone Enzalutamide + lutetium Lu 177 vipivotide tetraxetan Abiraterone + Docetaxel + lutetium Lu 177 vipivotide tetraxetan + Prednisone Abiraterone + lutetium Lu 177 vipivotide tetraxetan + Prednisone Apalutamide + lutetium Lu 177 vipivotide tetraxetan Darolutamide + Docetaxel + lutetium Lu 177 vipivotide tetraxetan Darolutamide + Docetaxel Abiraterone + Prednisone Apalutamide Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders) Recruiting FRA 0
NCT03827473 Phase II Abiraterone + Prednisone Docetaxel Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer (ACADEMIC) Terminated USA 0
NCT06520345 Phase III Abiraterone + Methylprednisolone Docetaxel + Prednisolone Abiraterone + Dexamethasone Docetaxel + Prednisone Abiraterone + Prednisone 177Lu-J591 + Docetaxel + Prednisone 177Lu-J591 + Enzalutamide + Prednisone 177Lu-J591 + Abiraterone + Methylprednisolone 177Lu-J591 + Abiraterone + Dexamethasone 177Lu-J591 + Docetaxel + Prednisolone Enzalutamide + Prednisolone Enzalutamide + Prednisone 177Lu-J591 + Enzalutamide + Prednisolone Abiraterone + Prednisolone 177Lu-J591 + Abiraterone + Prednisone 177Lu-J591 + Abiraterone + Prednisolone The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT GLOBAL) Recruiting USA | NZL | AUS 0
NCT01715285 Phase III Abiraterone + Prednisone A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC) Completed TUR | SWE | SVK | ROU | POL | NZL | NLD | ISR | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BGR | BEL | AUS | ARG 11
NCT04887506 Phase III Abiraterone + Prednisone Prednisone + TAVT-45 TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer Completed USA | SWE | POL | HUN | GBR | FRA | ESP 1
NCT04175431 Phase II Abiraterone + Prednisone Fluciclovine (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study Recruiting USA 0
NCT06320067 Phase III Darolutamide + lutetium Lu 177 vipivotide tetraxetan Abiraterone + lutetium Lu 177 vipivotide tetraxetan + Prednisolone Apalutamide + lutetium Lu 177 vipivotide tetraxetan Abiraterone + Docetaxel + lutetium Lu 177 vipivotide tetraxetan + Prednisolone Darolutamide Abiraterone + Docetaxel + Prednisone Enzalutamide + lutetium Lu 177 vipivotide tetraxetan Docetaxel + Enzalutamide + lutetium Lu 177 vipivotide tetraxetan Darolutamide + Docetaxel + lutetium Lu 177 vipivotide tetraxetan Apalutamide + Docetaxel + lutetium Lu 177 vipivotide tetraxetan Enzalutamide Apalutamide + Docetaxel Docetaxel + Enzalutamide Apalutamide Abiraterone + Prednisone Darolutamide + Docetaxel A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer (STAMPEDE2) Recruiting GBR 0
NCT06764485 Phase III Docetaxel + Prednisone Enzalutamide + Prednisolone Enzalutamide + Prednisone Abiraterone + Prednisone Docetaxel + Prednisolone Abiraterone + Prednisolone CC-94676 A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer (rechARge) Recruiting USA | TUR | SWE | SVK | ROU | POL | ITA | IRL | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | AUT | AUS | ARG 7
NCT04497844 Phase III Abiraterone + Niraparib + Prednisone Abiraterone + Prednisone A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (AMPLITUDE) Active, not recruiting USA | TUR | SWE | POL | NZL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BGR | BEL | AUS | ARG 12
NCT04787744 Phase II Goserelin Degarelix Relugolix Nilutamide Triptorelin Histrelin acetate Docetaxel + Prednisone Leuprolide Apalutamide Abiraterone + Prednisone Flutamide Abiraterone + Methylprednisolone Bicalutamide Docetaxel Enzalutamide Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (VA STARPORT) Recruiting USA 0
NCT01940276 Phase II Abiraterone + Prednisone Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer Completed USA 0
NCT05204927 Phase III Abiraterone + Enzalutamide lutetium Lu 177 vipivotide tetraxetan Abiraterone + Prednisone Lu-177-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer Active, not recruiting USA | ITA | FRA | ESP 0
NCT04647526 Phase III Abiraterone + Dexamethasone Abiraterone + Prednisone Enzalutamide PNT2002 Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH) Active, not recruiting USA | SWE | NLD | GBR | FRA | CAN 0
NCT06173362 Phase II Darolutamide Abiraterone + Prednisone Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer Recruiting USA 0
NCT03565835 Phase II Abiraterone + Prednisone Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer Active, not recruiting USA 0
NCT05288166 Phase III Abiraterone + Prednisone Abemaciclib + Abiraterone + Prednisone A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3) Active, not recruiting USA | TUR | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG 5
NCT06952803 Phase III Abiraterone + Prednisolone + Saruparib Abiraterone + Prednisone + Saruparib Abiraterone + Prednisone Saruparib Abiraterone + Prednisolone A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation (EvoPAR-PR02) Recruiting USA | TUR | SWE | POL | NLD | ITA | HUN | GBR | FRA | FIN | ESP | DEU | CAN | BRA | BEL | AUT | AUS | ARG 9
NCT03649841 Phase II Abiraterone + Prednisone Abiraterone + Prednisone + Radiotherapy Effects of Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Radiation on Prostate Cancer Terminated USA 0
NCT01688492 Phase Ib/II Abiraterone + Prednisone Ipilimumab Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer Active, not recruiting USA 0
NCT03012321 Phase II Abiraterone + Olaparib + Prednisone Abiraterone + Prednisone Olaparib Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects Active, not recruiting USA 0
NCT03511196 Phase I Abiraterone + Prednisone Leuprolide Goserelin Triptorelin Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer Active, not recruiting USA 0
NCT07005154 Phase II ASP5541 ASP5541 + Prednisolone Abiraterone + Prednisolone Abiraterone + Prednisone ASP5541 + Prednisone A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer Recruiting USA 2
NCT03834519 Phase III Abiraterone + Prednisone Enzalutamide Olaparib + Pembrolizumab Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010) Completed USA | NZL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CAN | BRA | AUT | AUS | ARG 5
NCT03016741 FDA approved Enzalutamide Abiraterone + Prednisone Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer Active, not recruiting USA 0
NCT01576172 Phase II Abiraterone + Prednisone Abiraterone + Prednisone + Veliparib Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Completed USA 0
NCT05276492 Phase I Abiraterone + Prednisone Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose. Terminated USA 0
NCT02218606 Phase II Cabazitaxel Abiraterone + Prednisone Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer Completed USA 0
NCT03833921 Phase II Abiraterone + Prednisone Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer (APRE) Recruiting USA 0
NCT04812366 Phase II Abiraterone + Apalutamide + Prednisone Apalutamide Abiraterone + Prednisone Apalutamide + Atezolizumab Abiraterone + Docetaxel + Prednisone Abiraterone + Niraparib + Prednisone Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer (GUNS) Recruiting USA | CAN 0
NCT04691804 Phase III Abiraterone + Fluzoparib + Prednisone Abiraterone + Prednisone A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Active, not recruiting USA | POL | HUN | GBR | FRA | ESP | CZE | BEL | AUS 4
NCT06136624 Phase III Dexamethasone + Fludrocortisone + ODM-208 Enzalutamide Abiraterone + Prednisone Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (OMAHA-003) Recruiting USA | TUR | SWE | POL | NZL | NOR | NLD | ITA | ISR | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | AUT | AUS | ARG 13
NCT03748641 Phase III Abiraterone + Niraparib + Prednisone Abiraterone + Prednisone A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer Active, not recruiting USA | TUR | SWE | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUS | ARG 10
NCT04291664 Phase I Abiraterone + Prednisone DST-2970 + Prednisone PK and Dose Escalation and Expansion Study of DST-2970 Terminated USA 0


Additional content available in Icon for CKB-BoostCKB BOOST